Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) EBIT (2016 - 2025)

Historic EBIT for Ani Pharmaceuticals (ANIP) over the last 15 years, with Q3 2025 value amounting to $36.2 million.

  • Ani Pharmaceuticals' EBIT rose 27661.68% to $36.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.9 million, marking a year-over-year increase of 51557.15%. This contributed to the annual value of $584000.0 for FY2024, which is 9875.67% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its EBIT stood at $36.2 million for Q3 2025, which was up 27661.68% from $13.9 million recorded in Q2 2025.
  • Ani Pharmaceuticals' EBIT's 5-year high stood at $36.2 million during Q3 2025, with a 5-year trough of -$23.7 million in Q4 2021.
  • In the last 5 years, Ani Pharmaceuticals' EBIT had a median value of $3.0 million in 2021 and averaged $2.6 million.
  • As far as peak fluctuations go, Ani Pharmaceuticals' EBIT plummeted by 726706.95% in 2021, and later soared by 45931.93% in 2023.
  • Ani Pharmaceuticals' EBIT (Quarter) stood at -$23.7 million in 2021, then soared by 107.67% to $1.8 million in 2022, then soared by 269.56% to $6.7 million in 2023, then crashed by 165.09% to -$4.4 million in 2024, then soared by 927.78% to $36.2 million in 2025.
  • Its EBIT was $36.2 million in Q3 2025, compared to $13.9 million in Q2 2025 and $26.2 million in Q1 2025.